Eli Lilly and Co. stock after-hours at EUR 1,018.00: minus 0.58 percent versus prior close
Published on 10/02/2026 at 17:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Co. stock traded at EUR 1,018.00 after-hours at 5:46 p.m. CEST on October 2, 2026, down 0.58 percent versus the Lang & Schwarz prior close of EUR 1,023.90.
Friday’s after-hours trading
The quoted price was EUR 1,018.00 at 5:46 p.m. CEST, compared with a bid of EUR 1,016.40 and an ask of EUR 1,019.60. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Eli Lilly and Co. stock.
Foundayo risk analyses
In a release dated October 1, 2026, Eli Lilly and Company reported post-hoc ATTAIN-1 analyses for Foundayo, orforglipron. At 72 weeks, estimated reductions in predicted 10-year type 2 diabetes risk versus placebo were 45.0 percent, 50.0 percent and 57.0 percent for the 5.5 mg, 9 mg and 17.2 mg doses, respectively. The 17.2 mg dose was also associated with an estimated 18.0 percent reduction in predicted cardiovascular disease risk versus placebo.
ACHIEVE-4 cardiovascular results
In a September 30, 2026 release, Eli Lilly and Company said Foundayo demonstrated non-inferior major adverse cardiovascular event risk versus insulin glargine in the Phase 3 ACHIEVE-4 trial. The company reported a 16.0 percent lower risk for MACE-4 and a 23.0 percent lower risk for MACE-3, while pre-planned analyses showed 53.0 percent lower cardiovascular death risk and 57.0 percent lower all-cause death risk versus insulin glargine.
